Oruka Therapeutics Inc. (ORKA)
NASDAQ: ORKA · Pharmaceutical Preparations · Menlo Park, CA
Our rating: Cautious
Call changed from Neutral to Cautious at $109.50, low conviction, November 10, 2026.
Breaks if: The Cautious call is wrong if the stock closes above $148 — roughly 35% above the current price — within six months (approximately 126 trading days), which would signal that a clinical readout, regulatory milestone, or partnership has validated the valuation in a way the current filings do not. It is also wrong if the company discloses a Phase 3-ready asset in a large indication with a near-term primary endpoint read, shifting the risk/reward clearly in the company's favor before the next two quarterly filings.
Key figures
| Market value | $6.5B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$153M |
| Free cash flow, last 12 months | −$124M |
| Price to earnings | n/a |
| Free cash flow yield | −1.9% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −18.1% |
| Beta to the S&P 500 | 1.24 |
| Volatility, annualized | 76.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | n/a | −$44M |
| June 30, 2026 | n/a | n/a | n/a | −$33M |
| March 31, 2026 | n/a | n/a | n/a | −$24M |
| December 31, 2025 | n/a | n/a | n/a | −$23M |
| September 30, 2025 | n/a | n/a | n/a | −$22M |
| June 30, 2025 | n/a | n/a | $-0.46 | −$23M |
| March 31, 2025 | n/a | n/a | $-0.40 | −$21M |
| December 31, 2024 | n/a | n/a | $2.21 | −$19M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 5%, Mistral 2%
21 ledger entries and 112 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.